SIRT2 and hepatocellular carcinoma: We surmised that this hypothesis of a “flip” in the role of Sirt2, from tumor suppressor in a normal liver context to tumor promotor in a tumor context, could be applied to the HCC literature, as female Sirt2−/− knockout mice in a controlled environment develop mammary or liver tumors, but inhibition of Sirt2 in well-established cancer cell lines suggest a tremendous therapeutic effect.